22-NHL-28-KP-PMC: A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma, ZUMA-22

Grants and Contracts Details

StatusActive
Effective start/end date3/6/2312/5/24

Funding

  • Kite Pharma Incorporated: $19,618.00